Drakos P, Bar-Ziv J, Catane R
Department of Oncology, Hadassah University Hospital, Jerusalem, Israel.
Am J Clin Oncol. 1994 Dec;17(6):502-5. doi: 10.1097/00000421-199412000-00010.
Tumor lysis syndrome (TLS), resulting from massive necrosis of neoplastic cells after chemotherapy, is a rare complication in nonhematologic malignancies. A 32-year-old woman suffering from a rapidly progressing breast adenocarcinoma metastatic to the liver and bones received a course of single-agent chemotherapy with mitoxanthrone and 4 days later developed the tumor lysis syndrome, and subsequently acute renal failure. The patient responded well to appropriate treatment. This case report points out that breast cancer can be extremely sensitive to chemotherapy and suggests that prophylaxis for tumor lysis syndrome should be considered in the subset of patients with breast carcinoma who have hepatic metastases and large tumor burdens.
肿瘤溶解综合征（TLS）是化疗后肿瘤细胞大量坏死所致，在非血液系统恶性肿瘤中是一种罕见的并发症。一名32岁女性患有迅速进展的转移性乳腺癌，已转移至肝脏和骨骼，接受了米托蒽醌单药化疗疗程，4天后出现肿瘤溶解综合征，随后发展为急性肾衰竭。患者对适当治疗反应良好。本病例报告指出，乳腺癌对化疗可能极其敏感，并建议对于有肝转移且肿瘤负荷大的乳腺癌患者亚组应考虑预防肿瘤溶解综合征。
